Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.54 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.53 |
| ▸ | PPM1D | O15297 | 2/20 | 0.52 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11061734 | 0.87 | CYP4A11 (0.53) | CYP4A11CYP4F2LOXL2EPHX1ALDH1A1 | |
| SCHEMBL11060354 | 0.87 | CYP4A11 (0.53) | CYP4A11CYP4F2LOXL2EPHX1ALDH1A1 | |
| SCHEMBL11061730 | 0.87 | CYP4A11 (0.53) | CYP4A11CYP4F2LOXL2EPHX1ALDH1A1 | |
| SCHEMBL11060332 | 0.87 | CYP4A11 (0.53) | CYP4A11CYP4F2LOXL2EPHX1ALDH1A1 | |
| SCHEMBL19922842 | 0.87 | CYP4A11 (0.60) | CYP4A11CYP4F2PPM1DLOXL2EPHX1 | |
| SCHEMBL27670154 | 0.85 | CYP4A11 (0.51) | CYP4A11CYP4F2LOXL2ALDH1A1SMN1; SMN2 | |
| SCHEMBL2252275 | 0.85 | CYP4A11 (0.51) | CYP4A11CYP4F2LOXL2ALDH1A1NPC1 | |
| SCHEMBL16664043 | 0.85 | RAB9A (0.50) | ALDH1A1NPC1SMN1; SMN2CYP1A2MEN1 | |
| SCHEMBL8703548 | 0.85 | CYP4A11 (0.51) | CYP4A11CYP4F2LOXL2EPHX1ALDH1A1 | |
| SCHEMBL15314408 | 0.84 | CYP4A11 (0.50) | CYP4A11CYP4F2LOXL2ALDH1A1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110023309-B | Indazole derivatives as glucagon receptor antagonists | 詹森药业有限公司 | 2022-08-09 | — | — | CN | disclosed |
| CN-109923109-B | Indazole derivatives as glucagon receptor antagonists | 詹森药业有限公司 | 2022-06-17 | — | — | CN | disclosed |
| US-20200377462-A1 | INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-03 | — | — | US | disclosed |
| US-10774048-B2 | Indazole derivatives useful as glucagon receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2020-09-15 | — | — | US | disclosed |
| EP-3510026-B1 | INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-12 | — | — | EP | disclosed |
| EP-3510028-B1 | INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-05 | — | — | EP | disclosed |
| US-20190218186-A1 | INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2019-07-18 | — | — | US | disclosed |
| EP-3510028-A1 | INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | Janssen Pharmaceutica NV (BE) | 2019-07-17 | — | — | EP | disclosed |
| EP-3510026-A1 | INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | Janssen Pharmaceutica NV (BE) | 2019-07-17 | — | — | EP | disclosed |
| CN-110023309-A | Indazole derivatives as glucagon receptor antagonists | 詹森药业有限公司 | 2019-07-16 | — | — | CN | disclosed |
| CN-109923109-A | Indazole derivatives as glucagon receptor antagonists | 詹森药业有限公司 | 2019-06-21 | — | — | CN | disclosed |
| US-10000473-B2 | Indazole derivatives useful as glucagon receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2018-06-19 | — | — | US | disclosed |
| WO-2018048762-A1 | INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2018-03-15 | — | — | WO | disclosed |
| WO-2018048763-A1 | INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2018-03-15 | — | — | WO | disclosed |
| US-20180065934-A1 | INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2018-03-08 | — | — | US | disclosed |
| US-20180065955-A1 | INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2018-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774048-B2 | Indazole derivatives useful as glucagon receptor antagonists | GPR119, GLP1R, GIPR | CYP4A11 448/4885CYP4F2 961/4885PPM1D 3658/4885 |
| US-20180065934-A1 | INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | GPR119, GLP1R, GIPR | CYP4A11 448/4885CYP4F2 961/4885PPM1D 3658/4885 |
| US-20200377462-A1 | INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | GPR119, GLP1R, GIPR | CYP4A11 448/4885CYP4F2 961/4885PPM1D 3658/4885 |
| US-20180065955-A1 | INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | GPR119, GLP1R, GIPR | CYP4A11 448/4885CYP4F2 961/4885PPM1D 3658/4885 |
| US-20190218186-A1 | INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | GPR119, GLP1R, GIPR | CYP4A11 448/4885CYP4F2 961/4885PPM1D 3658/4885 |
| US-10000473-B2 | Indazole derivatives useful as glucagon receptor antagonists | GPR119, GLP1R, GIPR | CYP4A11 448/4885CYP4F2 961/4885PPM1D 3658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.